Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 21, 2023
The politics of antimicrobial resistance (AMR) has changed substantially since we launched the first CGD working group on AMR in 2007. There is now much more awareness about the need to act, even if global solutions have not yet been implemented. Countries including the UK, Canada, and Japan have an...
Blog Post
September 19, 2023
Health systems in Africa are under considerable strain: rapid demographic change, rising non-communicable diseases, and emerging and re-emerging threats such as COVID-19 and Ebola are increasing demands on limited health services. The African Union’s admission to the G20 provides an opportunity for ...
Blog Post
September 19, 2023
September’s crisp fall weather is arriving, and with it, another annual United Nations General Assembly (UNGA), with thousands of people descending upon New York, buzzing about what should be the world’s priorities and objectives.
Fortunately, the world already has a set of #goals that were deve...
Blog Post
September 14, 2023
COVID-19 is fading from public discussion, countries’ , and hopes for a safer and fairer future are being dashed by potentially watered-down political commitments. Yet people around the world continue to feel the impacts of COVID-19 every day, other infectious disease threats have not magically gone...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...
Blog Post
August 22, 2023
A recent, thought-provoking blog by our colleague, Justin Sandefur, titled “How Economists got Africa’s AIDS Epidemic Wrong”, has sparked a debate about the historical role of cost-effectiveness analysis in assessing the investments of the President's Emergency Plan for AIDS Relief (PEPFAR) and, imp...